Drug Type Induced pluripotent stem cells (iPSC), Neural stem cell therapy |
Synonyms Allo iPS cell-derived dopamine neural progenitor, Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells, Dopaminergic neural progenitor cell therapy |
Target- |
Action- |
Mechanism Dopaminergic cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Parkinson Disease | Phase 2 | Japan | 24 May 2021 |





